40 results on '"Uriarte Isacelaya, E"'
Search Results
2. AB1008 BRIDGING THE GAP BETWEEN PATIENT’S PERCEPTION ON QUALITY OF LIFE AND DISEASE ACTIVITY AND DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENTS
3. AB0761 MULTICENTRIC SPANISH ANALYSIS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PATIENTS TREATED WITH MEPOLIZUMAB
4. OP0229 CHANGES IN THE CAUSES AND PREDICTORS OF LUPUS MORTALITY IN SPAIN THROUGH THE LAST DECADES: DATA FROM THE RELESSER REGISTRY
5. AB1677 VALIDATION ANALYSIS OF THE PHYSICIAN GLOBAL ASSESSMENT (PGA) SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS INCLUDED IN RELESSER-PROS REGISTRY
6. POS1508 PREVALENCE OF REMISSION ACCORDING TO PHYSICIAN AND PATIENT AND LEVEL OF AGREEMENT IN A REAL-WORLD MULTICENTER LUPUS REGISTRY
7. AB0594 CLINICAL SIGNIFICANCE OF ANTI-LA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS
8. AB0585 COMORBIDITY CLUSTERS AND THEIR RELATIONSHIP WITH SEVERITY AND OUTCOMES OF THE INDEX DISEASES, IN A LARGE MULTICENTER SYSTEMIC LUPUS ERYTHEMATOSUS COHORT (RELESSER REGISTER)
9. PO.7.156 Does expert opinion match the definitions of low disease activity state? Prospective analysis of 500 patients from a spanish multicenter cohort
10. S09.3 Changes in the causes and predictors of lupus mortality in Spain through the last decades: data from the relesser registry
11. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
12. AB0330 EXPERIENCE IN THE CURRENT PRACTICE WITH BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTICIAL LUNG DISEASE OF THE DONOSTIA UNIVERSITY HOSPITAL
13. POS0759 DOES LLDAS DEFINITION MATCH THE RHEUMATOLOGIST OPINION? THE FIRST VISIT EVALUATION OF A LONGITUDINAL SPANISH MULTICENTER STUDY TO ASSESS REASONS OF DISAGREEMENT.
14. POS0721 ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)
15. AB0230 OPTIMIZED TREATMENT OF BIOLOGICAL DISEASE MODIFYING DRUGS IN ROUTINE CLINICAL PRACTICE: SURVIVAL STUDY ANDANALYSIS OF PATIENT CHARACTERISTICS
16. FRI0201 OPHTHALMOLOGICAL FEATURES AT DIAGNOSIS AND IN RECURRENCES IN PATIENTS WITH GIANT CELL ARTERITIS CONFIRMED BY BIOPSY IN A TERTIARY HOSPITAL
17. AB1205 PARADOXICAL BIOLOGICS-INDUCED AUTOIMMUNE DISEASES
18. SAT0516 CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS IN PATIENTS WITH SECONDARY HEMOPHAGOCYTIC SYNDROME
19. THU0521 EVALUATION OF LIVER FIBROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDER METHOTREXATE TREATMENT. UTILITY OF FIBROSCAN AND BIOMARKERS IN ROUTINE CLINICAL PRACTICE.
20. FRI0481 HEMOPHAGOCYTIC SECONDARY SYNDROME. DIFFERENCES BETWEEN AUTOIMMUNE AND HEMATO-ONCOLOGICAL ETIOLOGIES
21. SAT0221 FACTORS AFFECTING MORTALITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN SPAIN IN THE 21ST CENTURY: DATA FROM THE RELESSER REGISTRY
22. Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
23. Hemophagocytic syndrome in patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)
24. CLINICAL SIGNIFICANCE OF ANTI-LA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS.
25. COMORBIDITY CLUSTERS AND THEIR RELATIONSHIP WITH SEVERITY AND OUTCOMES OF THE INDEX DISEASES, IN A LARGE MULTICENTER SYSTEMIC LUPUS ERYTHEMATOSUS COHORT (RELESSER REGISTER).
26. CHANGES IN THE CAUSES AND PREDICTORS OF LUPUS MORTALITY IN SPAIN THROUGH THE LAST DECADES: DATA FROM THE RELESSER REGISTRY.
27. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus
28. THU0542 Is there Any Difference Between Autoimmune or Hemato-Oncology Etiology to Guide us in the Diagnosis of Secondary Macrophage Activation Syndrome?: Table 1
29. MULTICENTRIC SPANISH ANALYSIS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PATIENTS TREATED WITH MEPOLIZUMAB.
30. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus
31. AB0921 Secondary Macrophage Activation Syndrome: Report of 13 Clinical Cases and the Difference between the 4 Groups of Diseases: Table 1
32. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus
33. Juvenile- and adult-onset systemic lupus erythematosus: A comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
34. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?
35. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
36. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER).
37. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
38. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
39. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry.
40. Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.